Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
PET Imaging Study of Recovered Anorexics
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 23
- Registration Number
- NCT00603018
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT00592852
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Hypoglycemia Associated Autonomic Failure in Type 1 DM
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 48
- Registration Number
- NCT00592670
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Butler Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT00578669
- Locations
- 🇺🇸
Butler Hospital, Providence, Rhode Island, United States
Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease
- Conditions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- Creighton University
- Registration Number
- NCT00573547
- Locations
- 🇺🇸
Creighton University Department of Psychiatry, Omaha, Nebraska, United States
🇺🇸Creighton Department of Psychiatry, Omaha, Nebraska, United States
Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Rafa Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00557427
- Locations
- 🇮🇱
Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 91
- Registration Number
- NCT00533117
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Study of Fluoxetine in Autism
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Neuropharm
- Target Recruit Count
- 158
- Registration Number
- NCT00515320
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States
🇺🇸University of California Davis, Sacramento, California, United States
🇺🇸University of Florida, Department of Psychiatry, Gainesville, Florida, United States
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
- Conditions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 403
- Registration Number
- NCT00485771
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00449007
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.